argenx SE is a biotechnology company focused on developing antibody-based therapies for severe autoimmune diseases. The company operates an antibody innovation ecosystem where scientists and engineers collaborate to discover novel therapeutic antibodies. Its proprietary pipeline includes product candidates such as efgartigimod, which is marketed for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and empasiprubart, aimed at treating severe IgM-driven autoimmune diseases.
